Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paliperidone ER in Acute Schizoaffective Disorder
NCT00412373Phase 3Completed
- Sponsor
- Johnson & Johnson
- Start
- Dec 2006
- Primary completion
- Jun 2008
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 3, randomised, double-blind trial in schizoaffective disorder comparing Paliperidone ER with Placebo (2 arms). Primary endpoint: Positive and Negative Symptoms of Schizophrenia Total Score at 6 weeks. Started Dec 2006; status: completed.
02
Drugs
paliperidone
03
Conditions
schizoaffective disorder
Beyond the preview
Go deeper on NCT00412373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00412373.